Cookson Peirce & Co. Inc. increased its holdings in Novartis AG (NYSE:NVS – Free Report) by 1.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,262 shares of the company’s stock after purchasing an additional 127 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Novartis were worth $733,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Aaron Wealth Advisors LLC increased its holdings in shares of Novartis by 21.6% during the 4th quarter. Aaron Wealth Advisors LLC now owns 5,904 shares of the company’s stock valued at $596,000 after acquiring an additional 1,050 shares during the last quarter. Syon Capital LLC acquired a new position in Novartis during the third quarter valued at approximately $6,568,000. Prime Capital Investment Advisors LLC raised its position in shares of Novartis by 368.3% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 20,251 shares of the company’s stock valued at $2,045,000 after purchasing an additional 15,927 shares during the period. Cerity Partners LLC lifted its stake in shares of Novartis by 30.8% in the fourth quarter. Cerity Partners LLC now owns 247,801 shares of the company’s stock worth $25,021,000 after buying an additional 58,395 shares during the last quarter. Finally, Mather Group LLC. boosted its holdings in shares of Novartis by 8.1% during the 3rd quarter. Mather Group LLC. now owns 7,763 shares of the company’s stock worth $791,000 after buying an additional 580 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.
Novartis Price Performance
NYSE NVS opened at $93.19 on Wednesday. Novartis AG has a twelve month low of $92.19 and a twelve month high of $108.78. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.93 and a current ratio of 1.15. The stock has a market capitalization of $197.53 billion, a PE ratio of 12.98, a P/E/G ratio of 1.47 and a beta of 0.54. The stock has a 50-day simple moving average of $98.61 and a 200 day simple moving average of $99.12.
Novartis Increases Dividend
The company also recently declared an annual dividend, which was paid on Thursday, March 7th. Investors of record on Friday, March 8th were paid a dividend of $3.7772 per share. This represents a yield of 3.1%. This is a positive change from Novartis’s previous annual dividend of $3.47. The ex-dividend date was Thursday, March 7th. Novartis’s payout ratio is currently 33.84%.
Analyst Ratings Changes
Several brokerages recently commented on NVS. BMO Capital Markets assumed coverage on shares of Novartis in a report on Friday, February 23rd. They issued a “market perform” rating and a $114.00 target price on the stock. Morgan Stanley initiated coverage on Novartis in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $114.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $104.33.
Check Out Our Latest Analysis on NVS
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
See Also
- Five stocks we like better than Novartis
- What is a Low P/E Ratio and What Does it Tell Investors?
- Prologis Stock Leading U.S. Logistics Boom
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
- Following Congress Stock Trades
- Are We in a Bull Market? 4 Factors that Determine a Bull Market
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.